Sector News

Want Actavis? Prepare to pay up, CEO says

February 19, 2015
Life sciences
Actavis CEO Brent Saunders expects pharma’s deal wave to continue. But make no mistake, he says: Potential suitors are going to have to pony up a pretty penny if they want to swallow his company.
 
The helmsman of the Dublin drugmaker–which is in the process of merging with Allergan after agreeing to buy the Botox maker for $66 billion–told analysts and investors Wednesday that he foresees “a continued consolidation” in pharma over the next several years, Reuters reports. But when it comes to his company’s role in that consolidation?
 
“I can’t predict what others will do, but I think it will take an awfully large premium to acquire a company this special,” he said.
 
It’s a message to those companies out there that may be looking to make a big splash in the M&A arena–like deal-hungry Pfizer, perhaps. The New York pharma giant is in need of a big buy after shutting down last year’s pursuit of AstraZeneca, and the rumor mill has been buzzing for some time now that it’s got its eye on Actavis to help it accomplish that.
 
As for Actavis’ own pickup action, though, it’ll be a little more subdued, Saunders said. While the company is constantly evaluating “dozens” of small acquisitions that align with its business, in terms of transformational deals, “we are going to take a pause,” he said, as quoted by the news service.
 
That’ll be somewhat of a break from Saunders’ recent deal spree, which sent him from Bausch + Lomb to Forest Labs to Actavis in quick succession. But right now, Actavis is putting its efforts into integrating Allergan and defining the combined company as a high-growth powerhouse with focuses on both branded and generic drugs.
 
“I’m excited about bringing these two companies together because I think we’re really going to have something exciting with this focus on growth pharma to rally around,” he told FiercePharma earlier this month. “I think this company is going to be a company that sets its own tone and does amazing things.”
 
By Carly Helfand
 

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach